The document is a regulatory filing regarding the availability of an audio recording for an Investor Conference Call focused on Q1 FY27 results.
The event type is specified as an Investor Conference Call with Senior Management of the company.
The call was held on July 30, 2026 (specific time not mentioned in the document).
The stated purpose of the event was to discuss Q1 FY27 results, as referenced in the subject line and previous intimation.
The document does not specify whether the meeting occurred before or after the formal earnings announcement.
No management participants or their designations are listed in this specific communication.
The audio recording of the call is available on the company's website at: https://www.mankindpharma.com/wpcontent/uploads/2026/07/Mankind-Q1-FY27-Audio.mp3.
The document does not contain any indication that unpublished price sensitive information (UPSI) was or will be shared.
Additional Notes Section
This communication serves as a follow-up to an earlier intimation dated July 17, 2026, under the subject 'Intimation of Investor Conference Call for Q1FY27 with Senior Management of Mankind Pharma Limited'.
The submission is made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
No financial data, guidance references, or presentation summaries are included in this specific announcement.
